Liver International最新文献

{"title":"A systematic PCR record-based re-call of HCV-RNA-positive people enables re-linkage to care and HCV elimination in Austria — The ELIMINATE project","authors":"Lorenz Balcar,&nbsp;Michael Schwarz,&nbsp;Livia Dorn,&nbsp;Mathias Jachs,&nbsp;Lukas Hartl,&nbsp;Lukas Weseslindtner,&nbsp;Nikolaus Pfisterer,&nbsp;Barbara Hennlich,&nbsp;Annika Stückler,&nbsp;Robert Strassl,&nbsp;Astrid Voill-Glaninger,&nbsp;Wolfgang Hübl,&nbsp;Martin Willheim,&nbsp;Karin Köhrer,&nbsp;Sonja Jansen-Skoupy,&nbsp;Sabine Tomez,&nbsp;Walter Krugluger,&nbsp;Christian Madl,&nbsp;Lukas Burghart,&nbsp;Lukas Antonitsch,&nbsp;Gerhard Weidinger,&nbsp;Florian Riedl,&nbsp;Hermann Laferl,&nbsp;Julian Hind,&nbsp;Christoph Wenisch,&nbsp;Christian Sebesta,&nbsp;Julia Wachter-Welzl,&nbsp;Paul Watzl,&nbsp;Magdalena Neuhauser,&nbsp;David Chromy,&nbsp;Mattias Mandorfer,&nbsp;Daniela Schmid,&nbsp;Michael Gschwantler,&nbsp;Thomas Reiberger,&nbsp;Andreas Maieron,&nbsp;David J.M. Bauer,&nbsp;Caroline Schwarz","doi":"10.1111/liv.16076","DOIUrl":"10.1111/liv.16076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Identification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal. Therefore, the ELIMINATE(ELIMINation of HCV in AusTria East) project aimed to systematically re-link people with a ‘last-positive’ HCV-RNA PCR record to care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In 10 major liver centres in Eastern Austria, a systematic readout of ‘last-positive’ HCV-RNA PCR test records obtained between 2008 and 2020 were conducted and linked to available patient contact data. Between 2020 and 2023, individuals were contacted first by phone, then by letter, to inform them about the availability of effective direct-acting antiviral (DAA) treatment and invite them for pre-treatment evaluation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The overall cohort of last-positive HCV+ individuals included 5695 subjects (62.5% males, mean age 57.3 ± 17.3 years); of note, 1931 (34%) of them had died and 759 (13%) individuals had no valid contact information. Of the remaining 3005 individuals, 1171 (40.0%) had already achieved sustained virological response (SVR) at the time of re-call. We successfully reached 617 (20.5%), of whom 417 (67.6%) attended their pre-treatment visit, and 397 (64.3%) commenced DAA-therapy. HCV cure has been confirmed in 326 individuals, corresponding to an SVR rate of 82.1%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The ELIMINATE project identified 5695 people living with HCV who were ‘lost to care’ despite documented HCV viraemia. While invalid contact data were an evident barrier to HCV elimination, premature deaths among the cohort underscored the severity of untreated HCV. The implementation of a systematic HCV-RNA PCR recorded-based re-call workflow represents an effective strategy supporting the WHO goal of HCV elimination.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3151-3163"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.16076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Follow-up post-HCV virological response to DAA in advanced chronic liver disease","authors":"A. Romano,&nbsp;N. Zeni,&nbsp;A. R. Caspanello,&nbsp;S. Phillips,&nbsp;S. S. Piano,&nbsp;P. Angeli","doi":"10.1111/liv.16113","DOIUrl":"10.1111/liv.16113","url":null,"abstract":"<p>Direct-acting antivirals (DAA) achieve high virological response rates with minimal side effects for many patients. Despite their significant impact on the progression and epidemiology of hepatitis C virus (HCV) associated liver disease, the global annual incidence of chronic infections is expected to remain relatively constant, averaging 1.42 million new cases each year until 2030. Furthermore, by 2030, there will be a 14–17% increase in end-stage liver disease outcomes such as liver-related deaths, hepatocellular carcinoma (HCC), and decompensated cirrhosis in adults aged 18 years and over. Although reductions in liver decompensation, HCC occurrence, and mortality have been shown in patients with advanced liver disease who achieved sustained virological response (SVR) with DAA, these benefits may be less significant in those with decompensated liver cirrhosis. This review aims to summarise the impact of the virological response to DAA on liver disease progression and outcomes in patients with advanced chronic liver disease, which appears to be crucial for defining patient-specific follow-up.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3138-3150"},"PeriodicalIF":6.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.16113","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it possible to make LI-RADS easier?","authors":"Merve Solak,&nbsp;Esat Kaba,&nbsp;Mehmet Beyazal","doi":"10.1111/liv.16058","DOIUrl":"10.1111/liv.16058","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3284"},"PeriodicalIF":6.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in hepatitis C among people aged 12–59 with no history of injection drug use, United States, January 2013–March 2020","authors":"Kathleen N. Ly,&nbsp;Laurie K. Barker,&nbsp;Greta Kilmer,&nbsp;Jaimie Z. Shing,&nbsp;Ruth B. Jiles,&nbsp;Eyasu Teshale","doi":"10.1111/liv.16108","DOIUrl":"10.1111/liv.16108","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>In the United States, hepatitis C virus (HCV) infection occurs primarily through injection drug use (IDU), but transmission also occurs through other ways. This study examined HCV prevalence and disparities among US residents aged 12–59 years with no IDU history.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analysed 2013-March 2020 National Health and Nutrition Examination Survey data to calculate the HCV prevalence among people with no drug use history and only a non-IDU history, collectively referred to as no IDU history. These estimates were compared to those with an IDU history and stratified by sociodemographic and hepatitis A and hepatitis B serologic characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The current HCV infection prevalence among people aged 12–59 was .7% overall, and specifically 17.2% among people with an IDU history, .9% among people with a non-IDU history and .2% among people with no drug use history. These rates represented 1.4 million people with current HCV infection, of whom, 730 000 had an IDU history, 262 000 had a non-IDU history and 309 000 had no drug use history. Among people with no drug use history, current HCV infection prevalence was higher for people born during 1954–1965 versus after 1965, had completed high school or less versus at least some college and had past/present hepatitis B versus vaccinated for hepatitis B.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While the HCV infection burden was highest among people with an IDU history, we found a sizeable burden among people without such a history. These findings support policies and practices aimed at addressing disparities among people needing treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3250-3259"},"PeriodicalIF":6.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to move beyond FIB-4 first for MASLD screening in Type 2 diabetes","authors":"Janakan Selvarajah,&nbsp;Ashok S. Raj","doi":"10.1111/liv.16057","DOIUrl":"10.1111/liv.16057","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3283"},"PeriodicalIF":6.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding ‘Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence’","authors":"Menglu Guo,&nbsp;Xiaoyuan Wei,&nbsp;Yu Min","doi":"10.1111/liv.16040","DOIUrl":"10.1111/liv.16040","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3279-3280"},"PeriodicalIF":6.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical industry payments and prescriptions of direct acting antiviral drugs for hepatitis C virus infection","authors":"Anju Murayama,&nbsp;Keith M. Sigel,&nbsp;Elizabeth S. Tarras,&nbsp;Deborah C. Marshall","doi":"10.1111/liv.16111","DOIUrl":"10.1111/liv.16111","url":null,"abstract":"&lt;p&gt;Hepatitis C virus (HCV) is a serious viral infection causing chronic HCV infection. Chronic HCV infection is the leading cause of hepatocellular carcinoma and liver transplantation in the United States (US).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In 2020, over 100 000 new cases of HCV and approximately 15 000 HCV-related deaths were reported in the US.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The treatment landscape for HCV has dramatically improved since the first direct-acting antiviral (DAA) was approved in 2011, achieving an eradication response rate exceeding 95%.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; However, the expensive cost of DAA treatment imposes a substantial financial burden on the US healthcare spending and patients. The recent introduction of several newer, less expensive DAAs has resulted in heightened competition among pharmaceutical companies and increased marketing activities of DAAs to physicians including HCV guideline authors.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Considering the competitive nature of the DAA market and findings from previous studies showing that the marketing payments to physicians are associated with increased prescriptions, we hypothesized that physician prescription patterns for DAAs would be associated with the payments from the pharmaceutical companies. Nevertheless, the associations of industry payments with physician DAA prescription practices had not been investigated.&lt;/p&gt;&lt;p&gt;This analysis used data from three publicly accessible databases: the Centers for Medicare &amp; Medicaid Services Medicare Part D, the Open Payments, and the Physician Compare databases. We focused on four DAAs currently recommended for initial HCV treatment in the US&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;: ledipasvir/sofosbuvir (Harvoni from Gilead Sciences, approved in October 2014), elbasvir/grazoprevir (Zepatier from Merck, approved in January 2016), sofosbuvir/velpatasvir (Epclusa from Gilead Sciences, approved in June 2016), and glecaprevir/pibrentasvir (Mavyret from AbbVie, approved in August 2017). Physician demographic characteristics were extracted from the Physician Compare database. The publicly accessible Medicare Part D database contains physician identifiers reporting more than 10 claims of a drug in a single year to protect patients' privacy. To encompass physicians who could prescribe DAAs, we extracted data on the 30-day standardized number of claims (including refills), Medicare spending, and total number of supply days associated with each DAA reported by physician prescribers from the Medicare Part D database for the years 2014 to 2021. General payments related to the four DAAs were collected from the Open Payments Database for the same period. This study included only physician prescribers, as the Open Payments Database covered payments to physicians only. The Mount Sinai institutional review board exempted this study from formal review, since this study only collected data from publicly available information and met the definition of non-human participant resea","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3274-3278"},"PeriodicalIF":6.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.16111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New insights in the pathogenesis of cirrhotic cardiomyopathy and the impact of left atrium strain","authors":"Marina Skouloudi,&nbsp;Magdalini Adamantou,&nbsp;Evangelos Cholongitas","doi":"10.1111/liv.16070","DOIUrl":"10.1111/liv.16070","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3285"},"PeriodicalIF":6.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142256620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response to Guo, Wei et al.","authors":"Stefano Ciardullo,&nbsp;Gianluca Perseghin","doi":"10.1111/liv.16067","DOIUrl":"10.1111/liv.16067","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"3281-3282"},"PeriodicalIF":6.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142256663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term cardiovascular risks associated with metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients","authors":"Jui-Ting Yu,&nbsp;Chen-Pi Li,&nbsp;Hui-Chin Chang,&nbsp;Shuo-Yan Gau","doi":"10.1111/liv.16053","DOIUrl":"10.1111/liv.16053","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 11","pages":"3100-3101"},"PeriodicalIF":6.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142256619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}